KPTI KARYOPHARM THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, KARYOPHARM THERAPEUTICS INC reported revenue of $33.4M (down 11.9% from a year earlier), net income of −$67.0M and diluted EPS of −$2.32; over the last four quarters revenue was $147M and net income −$225M; for the fiscal year ended December 2025 revenue was $146M, up 0.6% on the year before.

KPTI annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $146M, gross profit n/a, operating income −$90.7M, net income −$196M (margin -134.2%), EPS −$17.93
• Fiscal year ended Dec 2024: revenue $145M, gross profit n/a, operating income −$119M, net income −$76.4M (margin -52.6%), EPS −$14.00
• Fiscal year ended Dec 2023: revenue $146M, gross profit n/a, operating income −$130M, net income −$143M (margin -98.0%), EPS −$18.79
• Fiscal year ended Dec 2022: revenue $157M, gross profit n/a, operating income −$142M, net income −$165M (margin -105.2%), EPS −$2.02
• Fiscal year ended Dec 2021: revenue $210M, gross profit n/a, operating income −$98.3M, net income −$124M (margin -59.1%), EPS −$1.65

KPTI quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $33.4M (down 11.9% year over year), net income −$67.0M, EPS −$2.32
• Quarter ended Mar 31, 2026: revenue $35.1M (up 16.8% year over year), net income −$22.4M, EPS −$1.24
• Quarter ended Dec 31, 2025 (from the annual report): revenue $34.1M (up 11.6% year over year), net income −$102M, EPS −$7.02
• Quarter ended Sep 30, 2025: revenue $44.0M (up 13.6% year over year), net income −$33.1M, EPS −$3.82
• Quarter ended Jun 30, 2025: revenue $37.9M (down 11.4% year over year), net income −$37.3M, EPS −$4.32
• Quarter ended Mar 31, 2025: revenue $30.0M (down 9.4% year over year), net income −$23.5M, EPS −$2.77
• Quarter ended Dec 31, 2024 (from the annual report): revenue $30.5M (down 9.5% year over year), net income −$30.8M, EPS −$2.33
• Quarter ended Sep 30, 2024: revenue $38.8M (up 7.7% year over year), net income −$32.1M, EPS −$3.85
• Quarter ended Jun 30, 2024: revenue $42.8M (up 13.9% year over year), net income $23.8M, EPS −$2.97
• Quarter ended Mar 31, 2024: revenue $33.1M (down 14.4% year over year), net income −$37.4M, EPS −$4.85
• Quarter ended Dec 31, 2023 (from the annual report): revenue $33.7M (up 0.5% year over year), net income −$41.8M, EPS −$17.90
• Quarter ended Sep 30, 2023: revenue $36.0M (down 0.4% year over year), net income −$34.5M, EPS −$0.30
• Quarter ended Jun 30, 2023: revenue $37.6M (down 5.3% year over year), net income −$32.6M, EPS −$0.29
• Quarter ended Mar 31, 2023: revenue $38.7M (down 18.8% year over year), net income −$34.1M, EPS −$0.30
• Quarter ended Dec 31, 2022 (from the annual report): revenue $33.6M (down 73.4% year over year), net income −$38.5M, EPS −$0.42
• Quarter ended Sep 30, 2022: revenue $36.1M (down 4.1% year over year), net income −$36.3M, EPS −$0.45
• Quarter ended Jun 30, 2022: revenue $39.7M (up 75.6% year over year), net income −$49.1M, EPS −$0.62
• Quarter ended Mar 31, 2022: revenue $47.7M (up 104.9% year over year), net income −$41.4M, EPS −$0.53
• Quarter ended Dec 31, 2021 (from the annual report): revenue $126M, net income $38.7M, EPS $0.52
• Quarter ended Sep 30, 2021: revenue $37.7M, net income −$51.8M, EPS −$0.69

KPTI cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$75.4M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$127M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$92.7M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$150M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$107M, share buybacks n/a

KPTI balance sheet

• Jun 30, 2026: cash $55.0M, total assets $111M, total liabilities $441M, shareholders' equity −$330M
• Mar 31, 2026: cash $90.9M, total assets $131M, total liabilities $397M, shareholders' equity −$266M
• Dec 31, 2025: cash $60.5M, total assets $108M, total liabilities $401M, shareholders' equity −$293M
• Sep 30, 2025: cash $37.7M, total assets $96.2M, total liabilities $365M, shareholders' equity −$269M
• Jun 30, 2025: cash $38.7M, total assets $105M, total liabilities $344M, shareholders' equity −$239M
• Mar 31, 2025: cash $38.8M, total assets $128M, total liabilities $334M, shareholders' equity −$206M
• Dec 31, 2024: cash $62.5M, total assets $164M, total liabilities $350M, shareholders' equity −$186M
• Sep 30, 2024: cash $72.8M, total assets $189M, total liabilities $349M, shareholders' equity −$160M

What is KPTI's revenue?

KARYOPHARM THERAPEUTICS INC reported $147M of revenue over its last four quarters, through June 30, 2026.

Is KPTI profitable?

No. KARYOPHARM THERAPEUTICS INC lost $225M over the last four quarters.

What is KPTI's EPS?

Diluted earnings per share over the last four quarters were −$14.40; −$2.32 in the latest quarter.

KPTI ownership and insider trades · All stocks